Loading...
XNASNCNA
Market cap4mUSD
Dec 24, Last price  
1.21USD
1D
0.00%
1Q
-60.33%
IPO
-93.41%
Name

NuCana PLC

Chart & Performance

D1W1MN
XNAS:NCNA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.50%
Rev. gr., 5y
%
Revenues
0k
000283,000000000
Net income
-28m
L-13.71%
0-5,332,000-6,049,000-23,085,000-13,840,000-21,412,000-30,682,000-40,533,000-32,021,000-27,632,000
CFO
-26m
L+14.17%
0-4,467,000-9,264,000-8,708,000-12,224,000-23,833,000-21,619,000-23,824,000-23,158,000-26,439,000
Earnings
Mar 18, 2025

Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
URL
https://www.nucana.com/
IPO date
Sep 28, 2017
Employees
28
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
31,125
43,717
45,363
Unusual Expense (Income)
NOPBT
(31,125)
(43,717)
(45,363)
NOPBT Margin
Operating Taxes
(4,398)
(6,432)
(7,269)
Tax Rate
NOPAT
(26,727)
(37,285)
(38,094)
Net income
(27,632)
-13.71%
(32,021)
-21.00%
(40,533)
32.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
249
66
BB yield
-39.96%
-4.79%
Debt
Debt current
206
243
207
Long-term debt
586
1,035
535
Deferred revenue
Other long-term liabilities
58
46
46
Net debt
(16,433)
(40,637)
(59,522)
Cash flow
Cash from operating activities
(26,439)
(23,158)
(23,824)
CAPEX
(478)
(518)
(1,065)
Cash from investing activities
2,888
120
(3,561)
Cash from financing activities
(53)
(161)
(98)
FCF
(26,382)
(37,300)
(31,177)
Balance
Cash
17,225
41,912
60,264
Long term investments
3
Excess cash
17,225
41,915
60,264
Stockholders' equity
(126,419)
38,285
65,335
Invested Capital
141,760
740
5,531
ROIC
ROCE
EV
Common stock shares outstanding
2,107
2,089
2,082
Price
0.30
-55.18%
0.66
-72.27%
2.38
-46.99%
Market cap
623
-54.81%
1,379
-72.17%
4,954
-27.18%
EV
(15,810)
101,633
86,269
EBITDA
(30,550)
(42,985)
(44,421)
EV/EBITDA
0.52
Interest
1,103
9,859
Interest/NOPBT